L. Toral-Barza

发表

THE MAMMALIAN TARGET OF RAPAMYCIN ( MTOR ) AS A TARGET FOR CANCER CHEMOTHERAPY

J. Skotnicki, P. Frost, J. Gibbons, 2005 .

Synthesis and structure-activity relationships of 3-cyano-4-(phenoxyanilino)quinolines as MEK (MAPKK) inhibitors.

D. Powell, A. Wissner, M. B. Floyd, 2000, Bioorganic & medicinal chemistry letters.

Morpholine derivatives greatly enhance the selectivity of mammalian target of rapamycin (mTOR) inhibitors.

N. Brooijmans, L. Toral-Barza, K. Curran, 2009, Journal of medicinal chemistry.

ATP-competitive inhibitors of the mammalian target of rapamycin: design and synthesis of highly potent and selective pyrazolopyrimidines.

R. Abraham, N. Brooijmans, J. Gibbons, 2009, Journal of medicinal chemistry.

Biochemical, cellular, and in vivo activity of novel ATP-competitive and selective inhibitors of the mammalian target of rapamycin.

Kevin Curran, Judy Lucas, John Ellingboe, 2009, Cancer research.

mTOR complex-2 stimulates acetyl-CoA and de novo lipogenesis through ATP citrate lyase in HER2/PIK3CA-hyperactive breast cancer

L. Toral-Barza, Hui Zhao, Jianchang Qian, 2016, Oncotarget.

4-Substituted-7-azaindoles bearing a ureidobenzofuranone moiety as potent and selective, ATP-competitive inhibitors of the mammalian target of rapamycin (mTOR).

N. Brooijmans, N. Zhang, L. Toral-Barza, 2010, Bioorganic & medicinal chemistry letters.

Discovery and optimization of 2-(4-substituted-pyrrolo[2,3-b]pyridin-3-yl)methylene-4-hydroxybenzofuran-3(2H)-ones as potent and selective ATP-competitive inhibitors of the mammalian target of rapamycin (mTOR).

N. Brooijmans, L. Toral-Barza, J. Bard, 2010, Bioorganic & medicinal chemistry letters.

Discovery of 3,6-dihydro-2H-pyran as a morpholine replacement in 6-aryl-1H-pyrazolo[3,4-d]pyrimidines and 2-arylthieno[3,2-d]pyrimidines: ATP-competitive inhibitors of the mammalian target of rapamycin (mTOR).

N. Brooijmans, L. Toral-Barza, A. Zask, 2010, Bioorganic & medicinal chemistry letters.

Discovery of 2-ureidophenyltriazines bearing bridged morpholines as potent and selective ATP-competitive mTOR inhibitors.

L. Toral-Barza, J. Lucas, K. Curran, 2010, Bioorganic & medicinal chemistry letters.

Pyrazolopyrimidines as highly potent and selective, ATP-competitive inhibitors of the mammalian target of rapamycin (mTOR): optimization of the 1-substituent.

L. Toral-Barza, J. Lucas, K. Curran, 2010, Bioorganic & medicinal chemistry letters.

Discovery of 2-arylthieno[3,2-d]pyrimidines containing 8-oxa-3-azabi-cyclo[3.2.1]octane in the 4-position as potent inhibitors of mTOR with selectivity over PI3K.

L. Toral-Barza, A. Zask, J. Verheijen, 2010, Bioorganic & medicinal chemistry letters.

Discovery of lactoquinomycin and related pyranonaphthoquinones as potent and allosteric inhibitors of AKT/PKB: mechanistic involvement of AKT catalytic activation loop cysteines

R. Abraham, P. Cai, J. Levin, 2007, Molecular Cancer Therapeutics.

PWT-458, a novel pegylated-17-hydroxywortmannin, inhibits phosphatidylinositol 3-kinase signaling and suppresses growth of solid tumors

P. Frost, J. Skotnicki, P. Cai, 2005, Cancer biology & therapy.

Synthesis and structure-activity relationships of ring-opened 17-hydroxywortmannins: potent phosphoinositide 3-kinase inhibitors with improved properties and anticancer efficacy.

L. Toral-Barza, J. Lucas, M. Young, 2008, Journal of medicinal chemistry.

Calcium stores in cultured fibroblasts and their changes with Alzheimer's disease.

L. Toral-Barza, G. Gibson, H. Zhang, 1996, Biochimica et biophysica acta.

Selective Changes in Cell Bodies and Growth Cones of Nerve Growth Factor‐Differentiated PC12 Cells Induced by Chemical Hypoxia

L. Toral-Barza, Hui Zhang, G. Gibson, 1997, Journal of neurochemistry.

Cytosolic free calcium and ATP in synaptosomes after ischemia.

L. Toral-Barza, G. Gibson, H. M. Huang, 1991, Life sciences.

Cytosolic free calcium concentrations in synaptosomes during histotoxic hypoxia

L. Toral-Barza, Hsueh‐Meei Huang, G. Gibson, 1991, Neurochemical Research.

Neurotransmitters and Calcium During Hypoxia

L. Toral-Barza, G. Gibson, T. Manger, 1989 .

The role of cytosolic free calcium in the regulation of pyruvate dehydrogenase in synaptosomes

L. Toral-Barza, G. Gibson, K. R. Sheu, 2004, Neurochemical Research.

Discovery of 4-morpholino-6-aryl-1H-pyrazolo[3,4-d]pyrimidines as highly potent and selective ATP-competitive inhibitors of the mammalian target of rapamycin (mTOR): optimization of the 6-aryl substituent.

N. Brooijmans, L. Toral-Barza, J. Lucas, 2009, Journal of medicinal chemistry.

mTOR, a novel target in breast cancer: the effect of CCI-779, an mTOR inhibitor, in preclinical models of breast cancer.

P. Frost, J. Skotnicki, C. Discafani, 2001, Endocrine-related cancer.

Cytosolic-free calcium and neurotransmitter release with decreased availability of glucose or oxygen

L. Toral-Barza, G. Gibson, T. Manger, 1989, Neurochemical Research.

Inositol phosphates and intracellular calcium after bradykinin stimulation in fibroblasts from young, normal aged and Alzheimer donors

H. Thaler, L. Toral-Barza, G. Gibson, 1991, Neurobiology of Aging.

Interactions between inositol phosphates and cytosolic free calcium following bradykinin stimulation in cultured human skin fibroblasts.

L. Toral-Barza, G. Gibson, H. M. Huang, 1991, Biochimica et biophysica acta.

Cytosolic Free Calcium and Gene Expression During Chemical Hypoxia

L. Toral-Barza, G. Gibson, J. M. Carroll, 1992, Journal of neurochemistry.

Pyranonaphthoquinone lactones: a new class of AKT selective kinase inhibitors alkylate a regulatory loop cysteine.

D. Powell, J. Levin, L. Toral-Barza, 2009, Journal of medicinal chemistry.

Reproductive Cycle of the Cockle Anadara antiquata L. in Calatagan, Batangas, Philippines

L. Toral-Barza, E. Gomez, 1985 .

Beyond rapalog therapy: preclinical pharmacology and antitumor activity of WYE-125132, an ATP-competitive and specific inhibitor of mTORC1 and mTORC2.

R. Abraham, J. Gibbons, L. Toral-Barza, 2010, Cancer research.

Macroautophagy is dispensable for growth of KRAS mutant tumors and chloroquine efficacy

Gregory McAllister, Zuncai Wang, Gregory R. Hoffman, 2015, Proceedings of the National Academy of Sciences.

Requirement of the mTOR Kinase for the Regulation of Maf1 Phosphorylation and Control of RNA Polymerase III-dependent Transcription in Cancer Cells

M. Follettie, L. Toral-Barza, Jiang Wu, 2010, The Journal of Biological Chemistry.

Response and determinants of cancer cell susceptibility to PI3K inhibitors: Combined targeting of PI3K and Mek1 as an effective anticancer strategy

L. Toral-Barza, Wei-guo Zhang, A. Zask, 2008, Cancer biology & therapy.

A new pharmacologic action of CCI-779 involves FKBP12-independent inhibition of mTOR kinase activity and profound repression of global protein synthesis.

R. Abraham, J. Gibbons, L. Toral-Barza, 2008, Cancer research.

J. Skotnicki, C. Discafani, P. Frost, 2001 .

Cystine–glutamate antiporter xCT deficiency suppresses tumor growth while preserving antitumor immunity

Shibing Deng, R. Abraham, L. Toral-Barza, 2019, Proceedings of the National Academy of Sciences.

Characterization of the cloned full-length and a truncated human target of rapamycin: activity, specificity, and enzyme inhibition as studied by a high capacity assay.

J. Gibbons, L. Toral-Barza, J. Larocque, 2005, Biochemical and biophysical research communications.

MEK (MAPKK) inhibitors. Part 2: structure-activity relationships of 4-anilino-3-cyano-6,7-dialkoxyquinolines.

D. Powell, A. Wissner, C. Kohler, 2001, Bioorganic & medicinal chemistry letters.

Incorporation of water-solubilizing groups in pyrazolopyrimidine mTOR inhibitors: discovery of highly potent and selective analogs with improved human microsomal stability.

L. Toral-Barza, J. Lucas, K. Curran, 2009, Bioorganic & medicinal chemistry letters.

Biochemical and pharmacological inhibition of mTOR by rapamycin and an ATP-competitive mTOR inhibitor.

L. Toral-Barza, Ker Yu, L. Toral‐Barza, 2012, Methods in molecular biology.

Cytosolic free calcium in lymphoblasts from young, aged and alzheimer subjects

L. Toral-Barza, G. Gibson, L. Toral‐Barza, 1992, Mechanisms of Ageing and Development.